UM1AI068632-12: IMPAACT 2021: Randomized Phase IB Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/delta 1313/I1314L or RSV 276 or Placebo, Delivered as No

Project: Research project

Project Details

StatusFinished
Effective start/end date11/30/1711/29/18

Funding

  • Johns Hopkins University (5UM1AI068632-12)
  • National Institute of Allergy and Infectious Diseases (5UM1AI068632-12)